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Abstract
Background: IL-2 has been reported to be critical for peripheral Treg survival in mouse models. Here, we examined Treg
maintenance in a series of paediatric liver transplant recipients who received basiliximab, a therapeutic anti-CD25
monoclonal antibody.
Methodology/Principal Findings: FoxP3
+ CD4 T cells were analyzed by flow cytometry before liver grafting and more than
9 months later. We found that in vivo CD25 blockade did not lead to Treg depletion: the proportion of FoxP3
+ cells among
CD4 T cells and the level of FoxP3 expression were both unchanged. IL-2Rb expression was enhanced in FoxP3
+ cells both
before and after basiliximab treatment, while the level of IL-2Rc expression was similar in Tregs and non-Tregs. No significant
change in the weak or absent expression of IL-7Ra and IL-15Ra expression on FoxP3
+ cells was observed. Although the
proportion of FoxP3
+ cells among CD4 T cells did not vary, food allergies occurred more rapidly after liver grafting in
patients who received basiliximab, raising questions as to Treg functionality in vivo in the absence of functional CD25.
Conclusions: CD25 appears non essential for human Treg peripheral maintenance in vivo. However, our results raise
questions as to Treg functionality after therapeutic CD25 targeting.
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Introduction
Basiliximab is a humanized therapeutic monoclonal antibody
targeting the alpha chain of the IL-2 receptor (CD25) and used in
combination to induce immunosuppression during solid organ
transplantation [1]. Basiliximab binding can completely block the
interactions of IL-2 with IL-2Ra [2]. The IL-2Ra amino acids
responsible for IL-2 interaction overlap largely with the basiliximab
epitope[2,3].ThebindingaffinityofbasiliximabtoIL-2Ra(0.14 nM)
appears much higher than that of IL-2 to IL-2Ra (10 nM) [2,4]. This
therapeutic antibody targets activated CD4 T cells that transiently
expressCD25, therebypreventing IL-2-mediated T cellproliferation.
However, regulatory CD4 T cells also express CD25 constitutively.
Regulatory CD4 T cells are subdivided into natural and adaptive
Tregs [5]. Forkhead transcription factor (FoxP3) gene expression is
required for their development and function [6]. Tregs have
suppressive effects on T and B cells in humans and mice [6].
Multi-organ autoimmune disorders occur when this population is
removed from normal mice and when FoxP3 is mutated in both
humans and mice [6]. Tregs also inhibit T cell responses to tumours
and pathogens [7,8]. Finally, Tregs play a key role in allograft
acceptance. The indirect pathway of allo-recognition is particularly
important for the allo-tolerance role of Tregs [9]. Interleukin-2 has
been reported to be involved in Treg maintenance [6,10], in keeping
with the tolerogenic properties of this cytokine. Here, we examined
the in vivo effect of CD25 blockade by basiliximab on Tregs in young
children undergoing liver transplantation.
Results and Discussion
No significant change in the FoxP3
+ CD4 T cells subset
following in vivo CD25 blockade
After two injections of basiliximab, the proportion of
CD25
+FoxP3
+ cells among CD4 T cells fell sharply, while the
proportion of CD25
2FoxP3
+ cells increased and that of total
FoxP3
+ cell among CD4 T cells did not change significantly




cells also fell, from 23.867.3 cells/mm
3 to 0.9561.45 (mean 6
sem, p,0.01), while CD25
2FoxP3
+CD4
+ T cell numbers
increased from 4.062.3 cells/mm
3 to 25.5613.4 (p,0.01). The
absolute number of FoxP3
+ CD4
+ T cells did not change
significantly (28.169.1 versus 30.4614.4 cells/mm
3). This sug-
gests that basiliximab prevented binding of the anti-CD25 staining
antibody by occupying CD25 or downregulating its expression
[11], but that it did not lead to significant Treg depletion.
Following a nadir observed during the first month following liver
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+FoxP3
+ cells among circulating
CD4 T cells gradually increased, returning to pretransplantation




+ T cells from the nadir might have been due
to CD25 re-expression, but de novo Treg generation or Treg
redistribution from tissues to blood cannot be ruled out. As shown
in Fig. 1D, the level of intracellular FoxP3 expression in total
FoxP3
+ cells (based on the mean fluorescence intensity) did not
vary after basiliximab injection. No significant change in FoxP3
expression was found in the FoxP3
hi subset, which has been
reported to be highly suppressive in vitro [12].
A possible role for IL-2Rb in Treg maintenance
Although the situation in blood may not necessarily reflect
conditions in other tissues, basiliximab appeared to non specifically
reduce the proportion of FoxP3
+ cells among CD4 T cells. This
raises several questions, including how peripheral Tregs can persist
when deprived of functional CD25. Studies of mouse models
suggest that IL-2 signalling is critical for Treg homeostasis in vivo
[13,14]. The discrepancy between these reports and our present
findings could be related to species differences. Alternatively, the
signal mediated by the intermediate-affinity dimeric bc IL-2
receptor may be sufficient for human Treg maintenance in vivo.
There are three receptor chains for IL-2, namely IL-2Ra, IL-2Rb
and cc, which form different receptor complexes. A complex
comprising all three subunits binds IL-2 with high affinity and is the
receptor form found on activated T cells and Tregs. IL-2Rb and cc
form an intermediate-affinity complex, in the presence of ligand,
expressed on NK cells and macrophages [15], although IL-2Rb
alone has low affinity for IL-2and cc alone has no detectable affinity
[15].Heterodimerization ofIL-2Rb andcc inthepresenceofIL-2 is
necessary and sufficient for effective signalling, via activation of
Figure 1. No significant effect of a blocking anti-CD25 antibody on the proportion of human FoxP3





+ (1B) and total FoxP3
+ cells (1C) among CD4 T lymphocytes was determined before liver grafting and basiliximab





2 MFI ratios were used to compare the level of intracellular FoxP3 expression (see Methods). Means and SEM are shown. The Mann Whitney test
was used for statistical analysis. The number of patients tested at each time point is indicated. Only statistically significant differences are indicated.
doi:10.1371/journal.pone.0011784.g001
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IL-2Rb and cc, respectively, and also for STAT5 activation, which
is the main pathway through which IL-2R contributes to Treg
maintenance [10,16]. We examined IL-2Rb and c chain expression
on FoxP3
+ cells following basiliximab administration. Both at
baseline and after basiliximab administration, FoxP3
+ CD4 T cells
consistently expressed significant levels of CD122, while IL-2Rb
expression was very low in FoxP3
2 CD4 T cells (Fig. 2A, 2B). By
contrast, IL-2Rc was clearly expressed by FoxP3
+ and FoxP3
2
CD4 T cells, with no significant difference in the expression level
between the two subsets (Fig. 2A, 2C). Following basiliximab
administration, CD122 and c chain expression by Tregs and non
Tregs remained stable (Fig. 2B, 2C). The results suggest either that
IL-2promotesTregmaintenanceviathedimericbcreceptor,orthat
another cytokine is involved, such as IL-15, which also signals via
CD122 and the c chain, and activates STAT5 [10]. Interestingly,
mice lacking CD25 display a slight decrease in Tregs within the
thymus but not in the periphery, while mice deficient in CD122
show a profound reduction in both thymic and peripheral Tregs
[17]. Recent findings also suggest that weak IL-2 receptor signalling
is sufficient to support peripheral Treg homeostasis [18]. CD122
expression by Tregs may enable the persistence of an IL-2 signal
sufficient for Treg maintenance following both therapeutic CD25
blockade and IL-2 suppression by tacrolimus. Previous findings
show that T cell clonal expansion requires sustained IL-2R
signalling, which may imply continued expression of all three IL-
2R subunits [18,19]. This could explain how anti-CD25 prevents T
cell activation in vivo without affecting Treg peripheral homeostasis.
No significant change in IL-15Ra or IL-7Ra expression on
FoxP3
+ CD4 T cells following basiliximab administration
As mentioned above, another possibility is that Tregs use a
substitute cytokine such as IL-15 when CD25 is unavailable. We
found no significant IL-15Ra expression on the patients’ Tregs
before or after basiliximab injection (Fig. 2D). However, IL-15Ra
differs from IL-2Ra, in that it alone binds IL-15 with high affinity,
and IL-15 has been shown to act through a phenomenon of trans-
presentation, in which IL-15 bound to IL-15Ra on one cell
presents IL-15 and interacts with CD122 and the c chain on
another cell [20,21]. We also examined whether Tregs use another
T cell survival-associated cytokine such as IL-7, that shares with
IL-2 the common c-chain [20]. Human Tregs express low levels of
IL-7Ra, the specific receptor chain for IL-7 [22,23] (see also
Fig. 2A). Following basiliximab treatment, we observed no
significant change in CD127 expression on FoxP3
+ cells, which
might reflect increased use of IL-7 by Tregs after basiliximab
therapy (Fig. 2E). However, in mice, the low level of IL7Ra
expressed by Tregs may participate in the survival of FoxP3
low
CD4 T cells in situations of IL-2 signalling deprivation [24].
Basiliximab and food allergy
Another important issue is whether Treg immunosuppressive
functions are maintained during therapeutic CD25 blockade. This
question cannot be examined in vitro, owing to the limited size of
blood samples obtained from young children. Among the
mechanismsbywhich Tregcellsmight suppress conventionalFoxP3-
T cells, Treg competition for IL-2 may deprive effector CD4 T cells
Figure 2. Human FoxP3
+ CD4 T cells express high levels of IL-2 Rb. IL-2Rb (Fig. 2A, 2B), IL-2Rc (Fig. 2A, 2C), IL-15Ra (Fig. 2A, 2D) and IL-
7Ra (Fig. 2A, 2E) expression was analyzed by flow cytometry in FoxP3
+ and FoxP3
2 CD4 T cells before liver grafting and basiliximab injection
(Figs. 2B to 2E), and at various times thereafter (2B to 2E). Fig. A shows a representative pre-graft staining profile. Figs. 2B to 2E represent the mean
(SEM) MFI ratios (see Methods). The Wilcoxon test was used to compare FoxP3
+ and FoxP3
2 CD4 T cells. The Mann Whitney test was used to analyze
the time course of expression in a given cell subset. Only significant differences are indicated.
doi:10.1371/journal.pone.0011784.g002
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triggering apoptosis [25]. However, peripheral Foxp3
+CD4
+ Tc e l l s
from Il2
2/2 or Il2ra
2/2 mice have a suppressive capacity similar to
that of wild-type Tregs, suggesting that IL-2 signalling is not required
for Treg function [13,14]. Also, recent studies of adult renal
transplant recipients treated with basiliximab suggest that Treg
suppressive functions, tested in vitro, are maintained [26,27].
However, these in vitro results may not accurately reflect Treg
responsiveness in vivo, as previously reported for Treg proliferative
capacity [28]. No autoimmune disorders have so far been observed
in our series of pediatric transplant recipients, and none have been
reported in other series of pediatric transplant recipients who
received basiliximab during induction therapy [29,30]. Accumulat-
ing evidence points to a role of Tregs in immune tolerance of
allergens [31]. Severe food allergies have been reported in a familial
form of IPEX syndrome, in which the FoxP3 gene is mutated [32].
We have observed food allergies in 28% of 100 liver transplant
recipients treated with tacrolimus and basiliximab, 24% of 42
comparable patients treated with tacrolimus and steroids (no
significant difference) and 4.5% of 336 comparable patients treated
with cyclosporine, steroids and azathioprine (p,0.01, Mann
Whitney test). Interestingly, while the frequency of food allergies
was not significantly different between the patients receiving
tacrolimus and basiliximab and those receiving tacrolimus and
steroids, allergy emerged significantly more rapidly in patients
treated with tacrolimus and basiliximab (15 months [6 days-47
months] vs 36 months [15 days-104 months], mean and range,
p,0.05, Mann Whitney test). The time to allergy emergence after
liver transplantation was not significantly different between patients
receiving tacrolimus and steroids and those receiving cyclosporine,
steroids and azathioprine (38 months [15 days-85 months]; p,0.01
vs tacrolimus- and basiliximab-treated patients, Mann-Whitney test).
Food allergies are frequent in paediatric liver graft recipients treated
with tacrolimus [33], for unclear reasons. Among other possible
explanations, it has been suggested that tacrolimus may increase
intestinal permeability and exposure to dietary antigens while young
transplant recipients are emerging from the immune anergy
associated with chronic liver failure [34–36]. We cannot rule out
the possibility that induction therapy with basiliximab may hasten
the onset of clinical allergic manifestations through possible effects
on Treg function and therefore on Th-2 responses to allergens.
Conclusion
We show that therapeutic CD25 blockade does not impair the
survival of human peripheral FoxP3
+ CD4 T cells, including
FoxP3
hi cells. This could be because IL-2 Rb chain expression by
Tregs enables IL-2 binding, thus providing, together with the c
chain, the necessary survival signal. Alternatively, FoxP3
+ cells may
use other cytokines such as IL-15 or IL-7 to activate STAT5 and
provide survival signals, although we found no change in the
normally weak or absent expression of the corresponding specific
receptors at the Treg cell surface after basiliximab administration.
Although the proportion of FoxP3
+ cells among CD4 T cells did not
vary, we found that food allergies occurred more rapidly after liver
grafting in young children who received basiliximab, raising
questions as to Treg functionality after therapeutic CD25 targeting.
Methods
Ethics statement
For the biological study, data were analyzed anonymously. No
samples were conserved. Written informed consent was obtained
from the children’s parents. The Bice ˆtre hospital local ethics
committee waived the need for study approval. For the study of
food allergy frequencies following transplantation, data were
analyzed anonymously. The Bice ˆtre hospital local ethics commit-
tee waived the need for informed consent (which would be
impossible to obtain, the study having started in 1987) and ethics
committee approval for this retrospective observational study.
The biological study involved 102 children undergoing liver
transplantation (mean age 29 months; range: 6–77) at Bice ˆtre
university hospital from January 2007 to June 2009. The blood
samples used here were collected for routine haematological and
immunological tests prior to transplantation and during monitor-
ing, which included flow cytometric analysis of T cell subsets.
The indications for transplantation included biliary atresia,
Alagille syndrome, fulminant hepatitis, hepatoblastoma, and
glycogenosis type IV. Tacrolimus (PrografH, Astellas), a calci-
neurin inhibitor, was administered orally at an initial dose of
0.1 mg/kg per day; the dose was then adapted to achieve blood
trough levels of 8–12 ng/ml during the first month post-
transplantation and 5–8 ng/ml thereafter. Basiliximab (SimulectH,
Novartis Pharma S.A.) was administered intravenously at a unit
dose of 10 mg (body weight ,35 kg). All the patients were given a
first dose within 8 hours following graft reperfusion and a second
dose on day 4 post-transplantation.
Circulating Treg lymphocytes were analyzed before transplan-
tation and during the first year after transplantation in 500-ml
blood samples. Cells were stained in whole blood. Intracellular
FoxP3 expression in CD4
+ T lymphocytes was analyzed by flow
cytometry (FacsCanto, Beckton Dickinson) after surface staining
with anti-CD4-PC5 (Beckman Coulter), anti-CD3 APC-Cy7
(eBioscience) and anti-CD25 APC (Beckton Dickinson), as well
as anti-CD122 (IL-2Rb)-PE (Beckman Coulter), anti-CD127-PE
(Beckman Coulter), anti-IL-15 Ra-PE (eBioscience), or anti-
CD132 (IL-2Rc)-biotin, followed by streptavidin-PE (eBioscience).
For FoxP3 labelling, blood cells were lysed (Cell BD Pharm
Lyse
TM) then permeabilized (eBioscience FoxP3 Staining Buffer
Set) before intracellular staining with anti-FoxP3-FITC (clone
PCH 101, eBioscience). FoxP3
+ cells and CD25
+ cells were
determined on the basis of the isotype control in the CD3
+CD4
+
lymphocyte gate. The expression levels of intracellular FoxP3 and
cell-surface IL-2Rb, IL-2Rc, IL-7Ra and IL-15Ra in FoxP3
+
CD4 T cells were determined on the basis of the mean
fluorescence intensity (MFI). MFI data were normalized between
experiments by determining the MFI ratio (MFI of the positive
population/MFI of the negative population with reference to the
isotype control). The FoxP3
hi gate was defined on the basis of the
last quartile ($75%) of FoxP3 fluorescence values in the FoxP3
+
gate.
The retrospective observational study of food allergy frequen-
cies following liver transplantation involved 478 children (mean
age: 40 months, range: 3–182 months) who were grafted at Bice ˆtre
hospital from January 1987 to December 2006. The indications
for transplantation were similar to those indicated above.
Therapeutic immunosuppression was based on tacrolimus and
basiliximab in 100 patients, tacrolimus and corticosteroids in 42
patients, and cyclosporine, corticosteroids and azathioprine in 336
patients. Tacrolimus and basiliximab were administered as
described above. Cyclosporine, corticosteroids and azathioprine
were administered as previously reported [37]. Food allergies were
diagnosed on the basis of clinical findings, skin tests, and detection
of specific IgE. Clinical features included one or several of the
following manifestations: lip oedema (66%), angioedema (38% of
patients), urticaria (17%) and anaphylactic shock (6%). Allergens
included one or several of the following: peanut (38%), egg (30%),
hazelnut (25%), fish (21%), cow milk (13%), lentil (11%), wheat
(9%), soya (9%), pea (8%), mustard (8%), kiwi (6%), tomato (6%),
Basiliximab and Tregs
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(2%).
The Mann-Whitney and Wilcoxon tests were used for data
analysis.
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